Share

April 27, 2021; 96 (17) Editorial

The Benign Course of PLS

A Strong Point in Favor of an Earlier Differentiation From ALS

Federica Agosta, Massimo Filippi
First published February 26, 2021, DOI: https://doi.org/10.1212/WNL.0000000000011773
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
78

Share

Article Information

vol. 96 no. 17 783-784
DOI: 
https://doi.org/10.1212/WNL.0000000000011773
PubMed: 
33637628
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published February 26, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Federica Agosta, MD, PhD and
    2. Massimo Filippi, MD, FEAN, FAAN
  1. Federica Agosta, MD, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen, Roche, Philips: speaker honoraria

    Editorial Boards:

    1. (1) NeuroImage-Clinical, Section Editor, 2016-present (2) Frontiers in Neurology – Applied Neuroimaging, Associate Editor, 2017-present (3) Journal of Neurology, member of the Editorial Board, 2012-present (4) Journal of Neuroimaging, member of the Editorial Board, 2015-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. European Research Council, NeuroTRACK Principal Investigator, 2017-2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Massimo Filippi, MD, FEAN, FAAN
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries

    Editorial Boards:

    1. Editor-in-Chief (2012-present), Journal of Neurology; Associate Editor, Neurological Sciences (2016-present); Associate Editor, Human Brain Mapping (since 2020)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen Idec, Merck-Serono, Novartis

    Speakers' Bureaus:

    1. Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Commercial entity: Bayer 2) Commercial entity: Biogen-Idec 3) Commercial entity: Merck-Serono 4) Commercial entity: Novartis 5) Commercial entity: Roche 6) Commercial entity: Teva Pharmaceutical Industries

    Research Support, Government Entities:

    1. 1) Italian Ministry of Health; grant number: GR-2013- 02357415; role: co-investigator; duration: September 2016-December 2020 2) Italian Ministry of Health; grant number: RF-2018- 12366746; role: PI; duration: 15/06/2020 – 14/06/2023

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Fondazione Italiana Sclerosi Multipla (FISM) 2) ARiSLA (Fondazione Italiana di Ricerca per la SLA)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuroimaging Research Unit, Division of Neuroscience, and Neurology Unit, Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute; and Vita-Salute San Raffaele University, Milan, Italy.
  1. Correspondence
    Dr. Agosta agosta.federica{at}hsr.it
View Full Text

Article usage

Article usage: February 2021 to October 2021

AbstractFullPdfSource
Feb 2021005Highwire
Mar 2021007Highwire
Apr 20213425230Highwire
May 20212143018Highwire
Jun 202118397Highwire
Jul 202114367Highwire
Aug 20219632Highwire
Sep 202111011Highwire
Oct 202118631Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me